Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Warner Chilcott
With
Sanofi
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women at least 5 years postmenopausal
Subjects treated with any combination alendronate 10 mg daily or 70 mg once weekly or any combination of risedronate 5mg daily or 35 mg weekly for 3-5 years. Or subjects treated with any combination of alendronate 10 mg daily or 70 mg once weekly or any combination of risedronate 5mg daily or 35 mg weekly for greater than 5 years.
You may not be if
Presence of metabolic bone disease other than PMO
Use of any medication other than alendronate or risedronate within with in the past 6 months likely to interfere with skeletal homeostasis.
Uncontrolled hyperthyroidism. Previous history of malignancy except treated squamous cell or basal cell carcinoma of the skin.
Alcohol or drug abuse, current or within the past 5 years.
Allergy to tetracycline, Novocain, or Versed.
Hip anatomy not conducive to transiliac bone biopsy or DXA scan.
